Startup Grants, Subsidies, and Valuation Report Disclosure Under UP Policy

The UP Startup Policy, Grant Flow, and Valuation Report Disclosure

How Seed Grants, Infrastructure Subsidies, and Reimbursement Schemes Flow Through to Value — and What Your Valuation Report Must Say About Them

Startup Valuation & Policy  |  FY 2025-26

Key Findings

The UP Startup Policy 2020 (First Amendment 2022), administered through the StartInUP portal, provides four categories of direct financial support to recognised startups: (1) Sustenance Allowance of ₹17,500/month for 12 months; (2) Seed Capital / Marketing Assistance up to ₹7.5 Lakhs disbursed in milestone-linked tranches of 40%+30%+30%; (3) Prototype Grant of ₹5 Lakhs in a single tranche — with the 50% additional incentive clause explicitly not applicable to this grant; and (4) Reimbursement instruments including patent filing support (₹2 Lakhs for Indian patents, ₹10 Lakhs for international), and event participation reimbursement (₹50,000 national, ₹1 Lakh international). Infrastructure subsidies under the Policy flow primarily to incubators — not directly to startups — in the form of capital grants up to ₹1 Crore for technology infrastructure development and operational expenditure support of ₹30 Lakhs per year for five years.

On disclosure standards, the IBBI’s November 2025 Discussion Paper and accompanying draft Guidelines (19 November 2025) represent the most significant reform to valuation report requirements since the Companies (Registered Valuers and Valuation) Rules, 2017. The IBBI has identified non-uniform report formats, insufficient disclosure of assumptions, and inadequate methodology rationale as systemic failures generating litigation and impaired stakeholder confidence. The draft Guidelines mandate explicit basis of value, scope of work, methodology rationale, assumptions and limiting conditions, and supporting documentation. While these guidelines are formally directed at IBC proceedings, their disclosure principles represent the emerging standard for all registered valuer reports — including startup pre-money valuations.

The core technical question — how each UP Policy instrument should flow through to a DCF-based pre-money valuation and what must be disclosed in the report — is unresolved in any existing IBBI or ICAI technical guidance. This article establishes the practitioner framework.

A registered valuer preparing a pre-money opinion for a UP-recognised startup faces a question that has no published answer in IBBI circulars, ICAI technical guides, or the Companies (Registered Valuers and Valuation) Rules, 2017. The question is this: when a startup has received or is eligible to receive government grants, infrastructure subsidies, and reimbursement schemes under the UP Startup Policy, how exactly should each instrument flow through the valuation model — and what must the valuation report say about the treatment?

Founders want maximum credit. Investors want none of it. Tax authorities want a paper trail. And the registered valuer — whose report may be scrutinised in a funding due diligence, a Section 56(2)(x) tax proceeding, or an IBBI-style disclosure review — needs a defensible, documented position on every rupee of government support in the financial statements.

• The grants are real. The question is not whether they belong in the financials — they do. The question is how they flow through the valuation model, and whether the report explains that flow clearly enough to survive scrutiny.

Getting this wrong has asymmetric consequences. An overstated pre-money valuation that inflates government grants into recurring revenue will not survive a sophisticated investor’s due diligence. A valuation report that fails to disclose the normalisation treatment of those grants creates a regulatory exposure that has grown significantly since IBBI’s November 2025 push for mandatory disclosure standards.

How Each UP Policy Instrument Reaches the Startup — And What It Actually Is

The first step in any valuation treatment decision is understanding the precise legal and economic nature of each instrument. The UP Startup Policy provides support through three distinct channels that have fundamentally different characteristics for valuation purposes:

Channel One: Cash Grants — Sustenance Allowance and Seed Capital

Sustenance Allowance: ₹17,500 per month, paid directly to the startup for 12 months (extendable to 18 months on special grounds). This is an unconditional monthly cash grant — there is no performance condition, no repayment obligation, and no equity dilution. It flows into the startup’s bank account as Other Income under Indian accounting standards.

Seed Capital / Marketing Assistance: Up to ₹7.5 Lakhs, disbursed in three tranches — 40% as an advance, 30% on achieving Key Performance Targets committed by the startup to the Policy Implementation Unit (PIU), and 30% on completing a second set of milestones assessed by an evaluation committee led by experts from institutions including IIT Kanpur and IIM Lucknow. The conditionality is significant: the startup must formally commit KPTs after receiving the first tranche, and the second and third tranches are released only on the committee’s recommendation. This is not a guaranteed receipt.

Prototype Grant: Up to ₹5 Lakhs, disbursed in a single tranche for MVP development. Critically, the Policy explicitly states that the 50% additional incentive clause does not apply to this grant. This makes the Prototype Grant the simplest instrument in the framework — fixed quantum, single disbursement, no performance conditionality beyond initial eligibility.

Channel Two: Reimbursement Instruments

The UP Policy provides three reimbursement mechanisms that reach startups directly: patent filing reimbursement of ₹2 Lakhs for Indian patents and ₹10 Lakhs for international patents upon successful filing; event participation reimbursement of ₹50,000 for national events and ₹1 Lakh for international events; and subsidised incubation space at government-managed incubators for up to 12 months.

Reimbursements are economically different from grants. They represent the return of a cash outflow — the startup spends first, then receives a refund. In accounting terms, a patent reimbursement received after successfully filing a patent reduces the net cost of the intangible asset, not the revenue line. An event participation reimbursement reduces selling and marketing expense. These are not income items in the traditional sense, and their valuation treatment differs accordingly.

Channel Three: Infrastructure Subsidies — Incubator-Level Support

This is the most frequently misunderstood channel. Capital grants of up to ₹1 Crore for technology infrastructure development, and operational expenditure support of ₹30 Lakhs per year for five years, flow to incubators — not to individual startups. The startup’s benefit is indirect: access to better-equipped incubation facilities at subsidised rates, and free co-working space of a minimum 100 sq.ft during the incubation period.

Common Misconception: Founders routinely describe the ₹1 Crore incubator capital grant as part of their policy support package in investor decks and valuation briefs. It is not. That money goes to the incubator’s balance sheet, not the startup’s. What the startup receives is the benefit of that infrastructure — free access to facilities whose market rental value typically ranges from ₹8,000 to ₹15,000 per month. This is a benefit-in-kind, not a cash receipt, and must be treated accordingly.

How Each Instrument Flows Through to Pre-Money Value — The Technical Framework

Sustenance Allowance: Normalise Out, Disclose Explicitly

The Sustenance Allowance does not belong in the DCF cash flow projection. It is a time-limited, non-recurring, policy-dependent inflow that will not exist in the forecast period beyond Year 1, and no investor will pay a multiple on a government allowance. The correct treatment is to identify it in the base year financial statements, remove it from normalised EBITDA, and carry forward a clean, subsidy-free operating cash flow model.

The disclosure obligation is specific. The valuation report must state that Sustenance Allowance receipts have been identified and normalised out of the base year EBITDA, provide the quantum removed (monthly rate × months received), and confirm that the DCF projection does not assume continuation of this support. Absent this disclosure, an investor or tax authority reviewing the report cannot verify whether the EBITDA figure used as the DCF anchor is clean or contaminated.

Seed Capital: Tranche-by-Tranche Assessment, Capex Offset Treatment

The Seed Capital treatment requires a more nuanced approach than the Sustenance Allowance because of its milestone-contingent structure. The correct analytical sequence is:

• First tranche (40% = ₹3 Lakhs): If received, treat as a reduction in the startup’s net cash funding requirement. It is not revenue. It offsets the cash cost of MVP development. In the DCF, this means reducing the initial capex or working capital requirement in Year 1 by the amount received.
• Second and third tranches (30% + 30% = ₹4.5 Lakhs): These are contingent receipts. They are receivable only if the PIU and evaluation committee confirm milestone achievement. A valuer cannot include contingent future tranches in the model without documentation confirming milestones are met or realistically achievable. Including unearned grant tranches in the revenue or funding line is not a conservative assumption — it is a misrepresentation.
• Disclosure requirement: The report must state which tranches have been received, which are pending, the milestone conditions attached to pending tranches, and the basis on which the valuer has or has not included future receipts in the model.

Prototype Grant: Clean Capex Offset

The ₹5 Lakh Prototype Grant is the simplest to handle. If received, it reduces the net cash cost of MVP development by ₹5 Lakhs. It does not affect the revenue line. In the DCF, this means the startup’s Year 1 development capex is ₹5 Lakhs lower than it would have been without the grant — improving free cash flow in Year 1 only. The disclosure is straightforward: confirm receipt, state the quantum, confirm it has been treated as a capex offset and not as income.

Reimbursements: Net Cost Reduction, Not Income

Patent reimbursements reduce the net capitalised cost of the intangible asset. Event reimbursements reduce net marketing expense. Neither is income in the economic sense. In the DCF, both affect the cost base used to build the operating cost structure. The valuer should use the net cost — post-reimbursement — as the input for the forecast, and disclose in the report that costs have been presented on a net basis reflecting available policy reimbursements.

The important caveat: reimbursements are available only while the startup remains within the policy eligibility window. Post-policy, patent costs revert to full gross cost. If a startup’s forecast relies on sustained reimbursement income to maintain cost competitiveness, the valuer must model the transition to gross costs in the year the policy window closes — typically Year 2 or Year 3 of a five-year DCF projection.

Infrastructure Subsidy Benefit: Post-Incubation Cost Normalisation

The economic value of free incubation space is real but time-limited. The correct treatment is not to capitalise the benefit in Year 1, but to ensure the Year 2 and beyond cost structure accurately reflects market-rate office or co-working costs once the free period ends. This is a cost normalisation in the outer years of the projection, not a Year 1 income recognition question.

The terminal value implication is the most consequential. If a startup’s DCF is built with zero office costs because of free incubation in Year 1, and the terminal value is calculated as a multiple of Year 5 EBITDA, the model must ensure that Years 2–5 include realistic occupancy costs. Failing to do so inflates the terminal value — which for most early-stage startups represents 60–80% of the total DCF value — by an amount that compounds through the entire projection period.

Complete Treatment Reference — All UP Policy Instruments

THE DISCLOSURE OBLIGATION

What the Valuation Report Must Say — The Emerging Disclosure Standard

Until recently, the disclosure requirements for startup pre-money valuations were largely defined by professional practice norms rather than mandatory regulatory format. That is changing rapidly. The IBBI’s November 2025 Discussion Paper on Strengthening the Valuation Process identified non-uniform report formats, insufficient disclosure of assumptions, and inadequate methodology rationale as systemic failures generating recurrent litigation and impaired stakeholder confidence.

While the November 2025 Guidelines are formally directed at IBC proceedings, the disclosure principles they mandate are increasingly the de facto standard that any serious valuation report — including a startup pre-money opinion — must meet to survive due diligence, tax scrutiny, or regulatory review. The IBBI Liquidation Process (Second Amendment) Regulations, notified February 2026, further embedded these standards into formal regulation.

• The question is no longer what a valuation report may disclose about government subsidies. Under the emerging IBBI framework, the question is what it must disclose — and the answer is specific, documented, and auditable.

The Six Disclosure Elements for UP Policy Instruments

A valuation report for a UP-recognised startup must address six specific disclosure elements relating to government policy support:

• Identification of All Policy Receipts. The report must explicitly enumerate every UP Policy benefit received or receivable: the instrument type, the quantum, the disbursement date or expected date, and the applicable policy clause. This is a factual inventory, not a summary.
• Nature Classification. Each instrument must be classified as to its nature: recurring vs. one-time, cash vs. benefit-in-kind, unconditional vs. milestone-contingent. This classification drives the treatment decision and must be stated explicitly, not assumed.
• Treatment Decision and Rationale. For each instrument, the report must state the treatment applied in the DCF model and the reason for that treatment. ‘Sustenance Allowance of ₹2.1 Lakhs has been normalised out of base year EBITDA on the basis that it is a non-recurring, policy-dependent inflow that will not exist in the forecast period’ is a disclosure. ‘Government grants have been excluded’ is not.
• Quantified Impact. The report must state the quantified impact of each normalisation decision. If the Sustenance Allowance normalisation reduces the EBITDA used as the DCF anchor by ₹2.1 Lakhs, and the pre-money value changes by ₹8–12 Lakhs as a result, that delta should be stated. This enables the reader to test the materiality of the treatment decision.
• Post-Policy Cost Structure. The report must describe how the operating cost model transitions from the subsidised base year to a market-rate structure in Years 2 and beyond. This includes the assumption used for post-incubation occupancy costs, the period in which policy window is assumed to close, and the gross cost basis used for patent and event expenditure in later forecast years.
• Milestone and Contingency Status. For Seed Capital tranches 2 and 3, the report must state whether the KPTs have been committed, whether milestones have been achieved, and the basis on which future tranches have been included or excluded from the model. If excluded, state why. If included, provide the documentary evidence of milestone achievement reviewed by the valuer.

IBBI November 2025 Context: The IBBI’s draft Guidelines of 19 November 2025 specify that valuation reports must include: explicit Basis of Value, defined Scope of Work, methodology rationale with documented reasons for approach selection, and assumptions and limiting conditions listed explicitly. For startup valuations, the treatment of government grants and subsidies is precisely the category of ‘assumptions and limiting conditions’ that the IBBI’s disclosure push is designed to surface. A report that omits this treatment — or describes it in boilerplate language — will not meet the standard the IBBI is moving toward.

The 50% Additional Incentive — Valuation Implications for Qualifying Startups

The UP Startup Policy provides a 50% additional incentive on both Sustenance Allowance and Seed Capital — but not the Prototype Grant — for startups that meet one or more of the following conditions: women, Transgender, or Divyangjan cofounders holding more than 26% equity; registered offices or operations in Purvanchal or Bundelkhand regions; or cofounders from Economically Weaker Sections.

For a qualifying startup, the maximum Sustenance Allowance rises from ₹2.1 Lakhs to ₹3.15 Lakhs annually, and the maximum Seed Capital rises from ₹7.5 Lakhs to ₹11.25 Lakhs. The total maximum cash grant support available to a qualifying startup therefore increases from ₹14.6 Lakhs to approximately ₹19.7 Lakhs.

The valuation treatment of the additional 50% does not change. It is still a non-recurring, policy-dependent inflow and must still be normalised out of EBITDA and treated as a capex offset where applicable. What changes is the disclosure obligation — the report must identify the qualifying condition, confirm that the additional incentive has been recognised, and confirm that it has been normalised out on the same basis as the base amount.

There is one specific valuation implication worth noting. A startup that qualifies for the additional incentive because of women-cofounder equity holding above 26% has a governance and ownership structure that is a positive signal in a Scorecard or Risk Factor Summation approach. The additional incentive itself is normalised out. The ownership structure that qualifies for it can legitimately be reflected as a positive diversity and governance attribute in the qualitative overlay of the valuation — separate from and in addition to the quantitative DCF.

The Valuation Report Checklist — UP Policy Instruments

• Obtain the complete policy documentation. Request the StartInUP recognition letter, all disbursement confirmations, milestone commitment letters to the PIU, and evaluation committee approval records for tranches 2 and 3 of Seed Capital. Do not model future grant receipts without documentation.
• Build the base year P&L on a gross basis first. Include all policy receipts in the financial statements as received — Other Income for cash grants, reduced costs for reimbursements. Then identify and remove each item explicitly in the normalisation schedule.
• Maintain a separate normalisation schedule. The normalisation from reported EBITDA to DCF EBITDA should be presented as a standalone table in the working papers, with each adjustment line-itemed and cross-referenced to the source document.
• Build the post-policy cost structure explicitly. Identify the month in which each policy benefit is expected to expire. From that month, apply market-rate costs for office space, patent filings, and event participation in the forecast model.
• State the treatment of each instrument in plain language in the report. Use the six disclosure elements outlined above. Avoid generic language like ‘non-recurring items have been excluded.’ Be specific about each instrument, each quantum, and each treatment decision.
• Quantify the impact of your normalisation decisions. State the pre-money value on an unadjusted basis and on a normalised basis. The difference is the disclosure that allows a reader to test whether the treatment is material to the conclusion.
• Flag the incubator-level support separately. If the founder has presented infrastructure capital grants as part of the policy support package in their deck or brief, the valuation report must clarify that this support flows to the incubator and not to the startup. Failure to do so creates a misrepresentation risk in the report.

Why Disclosure Quality Is Now a Risk Management Question

• A valuation report that does not explain how it treated government grants is not a complete report. Under the disclosure standards that IBBI and SEBI are now driving, it is a liability.

The UP Startup Policy is one of India’s more structured and generous state support frameworks. It provides real cash, real cost reductions, and real runway to qualifying startups. None of that changes the fundamental valuation principle: government grants that are time-limited, non-recurring, and policy-dependent do not belong in a DCF that is meant to represent the sustainable economics of the business.

What has changed is the disclosure environment. The IBBI’s November 2025 push for standardised valuation report formats, explicit methodology rationale, and documented assumptions creates a regime in which a valuation report that fails to address government subsidies — in either direction — is increasingly exposed to challenge. The standard is not complicated. It requires identifying what was received, classifying its nature, stating the treatment, quantifying the impact, and explaining the post-policy cost transition.

For registered valuers working in the state-supported startup ecosystem, this framework — built around the specific instruments of the UP Startup Policy — is the reference methodology. As more Indian states develop quantified, structured support programmes, the discipline of separating policy support from business value, and disclosing that separation clearly in the report, will define the quality standard for startup valuation practice in India.